Core Viewpoint - Intellia Therapeutics, Inc. is facing a class action lawsuit due to alleged misleading statements regarding its drug development, particularly for NTLA-3001, which has led to significant stock price declines [4][5]. Group 1: Company Overview - Intellia Therapeutics is a genome editing company focused on developing curative therapeutics [3]. - The company received authorization from the UK's Medicine and Healthcare products Regulatory Agency for a Phase 1/2 study of NTLA-3001 targeting alpha-1 antitrypsin deficiency-associated lung disease on July 30, 2024 [3]. Group 2: Allegations in the Lawsuit - The lawsuit claims that Intellia's management made false or misleading statements about the viability of NTLA-3001's development and marketing potential [4]. - It is alleged that the company provided overly optimistic timelines for drug dosing and future studies, which did not align with reality [4]. - The complaint states that Intellia was not adequately prepared to dose patients with NTLA-3001 or maintain its research and development efforts due to the challenges of viral-based editing methods [4]. - The lawsuit also highlights that even if NTLA-3001 was successful, the use of viral-based editing drugs is costly and inefficient [4]. Group 3: Impact on Stock Price - Following the announcement of a company reorganization on January 9, 2025, which included the discontinuation of NTLA-3001, Intellia's stock price fell by more than 15% [5].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Intellia Therapeutics, Inc. securities during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1][2]. Group 1: Class Action Details - Investors who bought Intellia securities between July 30, 2024, and January 8, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [1]. - A class action lawsuit has already been filed, and interested parties can join by submitting a form or contacting the law firm [2][5]. - The deadline to move the Court to serve as lead plaintiff is April 14, 2025 [2]. Group 2: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest settlement against a Chinese company at the time and being ranked No. 1 for securities class action settlements in 2017 [3]. - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [3]. - Founding partner Laurence Rosen has been recognized as a Titan of Plaintiffs' Bar by Law360 [3]. Group 3: Case Background - The lawsuit alleges that Intellia provided misleading information regarding its Phase 1/2 study for NTLA-3001, particularly about the timeline for dosing the first patient [4]. - It is claimed that Intellia failed to disclose the declining demand for viral-based editing methods, which could render NTLA-3001 an inefficient program [4].

Core Viewpoint - Intellia Therapeutics has initiated the first patient dosing in the MAGNITUDE-2 Phase 3 trial for nexiguran ziclumeran (nex-z), targeting hereditary ATTR amyloidosis with polyneuropathy, which could potentially redefine treatment paradigms for this debilitating disease [1][2][3]. Group 1: Clinical Trial Details - The MAGNITUDE-2 study is a pivotal Phase 3, randomized, double-blind, placebo-controlled trial involving approximately 50 patients with ATTRv-PN [4]. - The primary endpoints include a modified neuropathy impairment score and changes in serum TTR levels, with patients randomized to receive either a single 55 mg infusion of nex-z or a placebo [4]. - Intellia aims to submit a biologics licensing application (BLA) for ATTRv-PN by 2028, following the presentation of longer-term data from Phase 1 studies later this year [3][4]. Group 2: Product Information - Nexiguran ziclumeran (nex-z) is based on CRISPR/Cas9 technology and is designed to inactivate the TTR gene responsible for producing the mutated transthyretin protein [5]. - Interim Phase 1 data indicated that a single dose of nex-z resulted in consistent, deep, and long-lasting reductions in TTR levels [5]. - Nex-z has received Regenerative Medicine Advanced Therapy designations from the U.S. FDA for both polyneuropathy and cardiomyopathy, as well as Orphan Drug Designation from both the U.S. FDA and European Commission [5]. Group 3: Disease Background - Transthyretin amyloidosis (ATTR) is a rare, progressive, and fatal disease, with hereditary ATTR (ATTRv) caused by mutations in the TTR gene leading to the production of abnormal TTR proteins [6]. - Approximately 50,000 individuals globally are affected by ATTRv amyloidosis, with no known cure and limited treatment options available to slow the progression of the disease [6].

Core Insights - Intellia Therapeutics has initiated the first patient dosing in the MAGNITUDE-2 Phase 3 trial for nexiguran ziclumeran (nex-z), targeting hereditary ATTR amyloidosis with polyneuropathy [1][2] - The trial aims to evaluate the efficacy and safety of nex-z, which has the potential to redefine treatment for this debilitating disease [2][4] - The company plans to submit a biologics licensing application for ATTRv-PN by 2028, following promising Phase 1 data [3][5] Company Overview - Intellia Therapeutics is a clinical-stage gene editing company focused on CRISPR-based therapies, aiming to address significant unmet medical needs [7][8] - The company is developing nex-z as a one-time treatment for transthyretin amyloidosis, leveraging CRISPR/Cas9 technology [5][6] - Intellia has received Regenerative Medicine Advanced Therapy designations from the U.S. FDA for both cardiomyopathy and polyneuropathy indications [5] Clinical Trial Details - The MAGNITUDE-2 study is a randomized, double-blind, placebo-controlled trial involving approximately 50 patients [4] - The primary endpoints include a modified neuropathy impairment score and changes in serum TTR levels [4] - Patients will be randomized to receive either a single 55 mg infusion of nex-z or a placebo [4] Disease Context - Transthyretin amyloidosis (ATTR) is a rare and progressive disease, with hereditary forms (ATTRv) caused by mutations in the TTR gene [6] - There are an estimated 50,000 individuals with hereditary ATTR amyloidosis and between 200,000 to 500,000 with wild-type ATTR amyloidosis [6] - Current treatments are limited to slowing the accumulation of misfolded TTR proteins, with no known cure available [6]

Core Viewpoint - Intellia Therapeutics, Inc. is facing a class action lawsuit due to alleged misleading statements regarding its NTLA-3001 program for treating alpha-1 antitrypsin deficiency-associated lung disease, which has been discontinued following a company reorganization [2][3]. Summary by Relevant Sections Company Overview - Intellia Therapeutics, Inc. (NASDAQ: NTLA) is involved in developing treatments for genetic diseases, with a focus on viral-based editing technologies [2]. Allegations - The lawsuit claims that Intellia's management provided investors with optimistic timelines for the NTLA-3001 study, stating that the first patient would be dosed in the second half of 2024 [2]. - It is alleged that the company failed to disclose a significant decline in demand for viral-based editing methods, as non-viral delivery systems gained traction due to their cost-effectiveness and efficiency [2]. Company Actions - On January 9, 2025, Intellia announced a halt to all NTLA-3001 research and a workforce reduction of 27% in 2025, indicating a strategic shift in focus towards other pharmaceutical developments [2]. - Following this announcement, Intellia's stock price dropped from $12.02 per share on January 8, 2025, to $10.20 per share on January 10, 2025 [2]. Class Action Details - Shareholders who purchased NTLA shares between July 30, 2024, and January 8, 2025, are encouraged to register for the class action lawsuit, with a deadline of April 14, 2025, to seek lead plaintiff status [3]. - Participants will be enrolled in a portfolio monitoring system to receive updates on the case [3]. Legal Representation - The Gross Law Firm is leading the class action, emphasizing its commitment to protecting investors' rights against deceitful practices [4].

Core Viewpoint - Intellia Therapeutics, Inc. is facing a class action securities lawsuit due to alleged securities fraud that affected investors between July 30, 2024, and January 8, 2025 [1] Group 1: Lawsuit Details - The lawsuit aims to recover losses for investors impacted by the failure to disclose critical information regarding Intellia's Phase 1/2 study of NTLA-3001 for treating alpha-1 antitrypsin deficiency-associated lung disease [2] - Defendants allegedly misled investors by expressing confidence in the study's timeline, stating that the first patient would be dosed in the second half of 2024, while failing to disclose a decline in demand for viral-based editing methods [2] - The truth about the company's situation was revealed on January 9, 2025, when Intellia announced a halt to all NTLA-3001 research and a 27% workforce reduction, leading to a significant drop in stock price from $12.02 to $10.20 per share [2] Group 2: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until April 14, 2025, to request appointment as lead plaintiff, although participation does not require this role [3] - Class members may be entitled to compensation without any out-of-pocket costs or fees [3] Group 3: Firm Background - Levi & Korsinsky has a strong track record in securities litigation, having secured hundreds of millions for shareholders over the past 20 years and consistently ranking among the top securities litigation firms in the U.S. [4]

Core Viewpoint - Intellia Therapeutics, Inc. is facing a class action securities lawsuit due to alleged securities fraud that affected investors between July 30, 2024, and January 8, 2025 [1][2] Group 1: Lawsuit Details - The lawsuit aims to recover losses for Intellia investors who were impacted by the company's failure to disclose critical information regarding its Phase 1/2 study of NTLA-3001 for treating alpha-1 antitrypsin deficiency-associated lung disease [2] - Defendants allegedly misled investors by expressing confidence in the study's timeline, stating that the first patient would be dosed in the second half of 2024, while failing to reveal a significant decline in demand for viral-based editing methods [2] - On January 9, 2025, Intellia announced a reorganization, halting all NTLA-3001 research and reducing its workforce by 27%, which led to a significant drop in stock price from $12.02 on January 8, 2025, to $10.20 on January 10, 2025 [2] Group 2: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until April 14, 2025, to request appointment as lead plaintiff, although participation does not require this role [3] - Class members may be entitled to compensation without any out-of-pocket costs or fees, ensuring no financial obligation to participate [3] Group 3: Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions for shareholders over the past 20 years and consistently ranking among the top securities litigation firms in the United States [4]

The collaboration with Regeneron for nex-z is a boost for Intellia as it provides the latter with resources to support the development of the candidate. NTLA's Another Candidate NTLA-2002 & Other Developments Intellia Therapeutics, Inc. (NTLA) is developing its lead CRISPR-based, in vivo genome-editing candidate, nexiguran ziclumeran (nex-z, formerly known as NTLA-2001) for the treatment of transthyretin (ATTR) amyloidosis. Intellia has collaborated with Regeneron Pharmaceuticals (REGN) for the development ...

NEW YORK, March 31, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Intellia Therapeutics, Inc. (NASDAQ: NTLA). Shareholders who purchased shares of NTLA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/intellia-therapeutics-inc-loss-submission-form/?id=139401&from=4 CLASS PE ...

NEW YORK, March 28, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Intellia Therapeutics, Inc. ("Intellia" or the "Company") (NASDAQ: NTLA) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Intellia investors who were adversely affected by alleged securities fraud between July 30, 2024 and January 8, 2025. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com/pslra-1/intellia-therapeutics ...